Perth-based medicinal cannabis producer Little Green Pharma (ASX: LGP) has taken delivery of the first shipment of cannabis flower medicines from its new growing facility in Denmark.
The company imported approximately 50 kilograms of “Billy Buttons” THC (tetrahydrocannabinol) flower, approximately two months after finalising the $21.4 million acquisition.
Named after an Australian wildflower, the medicine has a THC content of 16% and is available for sale in 15g packs through pharmacies nationwide.
It has been is grown under Good Agricultural and Collection Practices (GACP), manufactured under EU Good Manufacturing Practices (EU GMP), and conforms with Therapeutic Goods (TGO 93) Order 2017.
Little Green Pharma is expecting two further shipments of cannabis flower medicines from Denmark totalling approximately 65kgs to arrive before end October.
Dried flower medicine sales in Australia have seen an increase in demand as doctors become more comfortable with the method of administration.
Cannabis flower is frequently prescribed as a breakthrough pain treatment or to assist with sleep, due to its rapid onset of therapeutic benefit.
Milestone achievement
Managing director Fleta Solomon said the first shipment within two months of the Danish facility’s acquisition was a “milestone achievement” for the company.
“To be able to meet all the regulatory requirements to supply and import product within a short timeframe is consistent with our reputation as a leading global medicinal cannabis business,” she said.
“Flower medicines are becoming increasingly popular with Australian doctors for their quick onset of effects and with access to this Denmark-grown product, we are able to provide a new supply chain of high-quality, medicinal cannabis flower in an under-supplied market.”
Key appointments
Little Green Pharma has appointed Morten Snede and Tony Roberts to the key roles of chief financial officer and group general manager (European Union) respectively.
Mr Snede brings more than 20 years experience from various senior managerial positions in the financial and maritime industries.
In 2018, he joined Canada’s Canopy Growth Corporation responsible for the development of the Danish facility, which Little Green Pharma acquired in June.
Mr Snede has served on several boards within the maritime industry and has been chairman of Denmark’s Medical Cannabis Industry Association.
Mr Roberts was previously the managing director of Tasmanian Botanics Pty Ltd, during which time he established a fully-integrated seed-to-sale medicinal cannabis facility engaged in cultivation, genetic research and manufacturing in Australia and capable of producing substantial quantities of dry biomass.
“Both men have a huge amount of industry expertise, having overseen the creation and development of significant medicinal cannabis businesses in their own right,” Ms Solomon said.
“We are very excited that they have agreed to join [our] team and help realise our ambition of continuously improving patient access to cannabis medicines and being the world’s leading pure-play medicinal cannabis supplier.”
